I thought the earnings were pretty decent. Obviously the market disagrees but I would love to hear your opinions of the earnings and today’s consequent drop in price.
02:35 AM EST, 02/10/2026 (MT Newswires) -- GSK (GSK.L) said China's Center for Drug Evaluation accepted for review its application for Arexvy as a vaccine in adults against respiratory syncytial virus-caused lower respiratory tract disease. According to a Tuesday filing, the British drugmaker is seeking approval in China for the use of the vaccine in adults aged at least 60 years. It supported the application with positive data from a phase 3 trial, and a regulatory decision is expected in 2027.
I thought the results today were decent, nice dividend growth for the upcoming and next year as well as the share buybacks. Market seems happy with the results what do you all think?
News on a new purchase for $GSK to strengthen its position in respiratory, immunology & inflammation offerings.
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buy-rapt-therapeutics-22-billion-2026-01-20/
GSK Q3 2025 Earnings in 5 Days: Execution vs. FX & IRA headwinds
When: Wed 29 Oct 2025, 07:00 GMT; management presentation follows (webcast link on GSK IR).
Street sees steady quarter with specialty meds leading; focus on whether FY25 stays “top-end” of guidance as FX and US policy headwinds bite.
4 Key Takeaways
• Consensus (Q3’25E): Turnover £8.24bn, Core EPS ~47.1p, Op. margin ~32.4%; WANS ~4,036m (buybacks reduce share count).
• FY25 Guidance (CER): Sales +3–5%, Core OP +6–8%, Core EPS +6–8%, management guiding toward the top end.
• Returns: FY25 dividend run-rate ~64p indicated earlier; £2bn buyback programme underway (three tranches completed/underway YTD).
• Watchpoints (Q3): FX −1% to −2% drag on sales; US IRA Part D redesign ~£400–500m FY headwind; step-up in SG&A to support launches; vaccine mix (Shingrix/Arexvy seasonality) and oncology momentum (Jemperli/Ojjaara).
⭐ Star Rating
• Dividend Strength: ⭐⭐⭐⭐☆
• Financial Health: ⭐⭐⭐⭐☆
• Growth/Pipeline: ⭐⭐⭐☆☆
• Valuation: ⭐⭐⭐☆☆
• Management/Execution: ⭐⭐⭐⭐☆
Overall: ⭐⭐⭐⭐☆ (4/5) Solid execution and shareholder returns; mind FX/IRA and vaccine mix into Q4.
If specialty meds + oncology keep comping strong and FX/IRA headwinds are contained, GSK can hold the top-end FY25 guide. I’ll be watching EPS leverage vs. SG&A step-up and any colour on Arexvy/Shingrix trajectory into Q4.
ccc1990
před 8 měsíci
Lovely stuff
ContrarianCNT
před 8 měsíci
What's happening guys?
Unable to check what's going on. Biggest daily pop I can remember on GSK.
Tato stránka může obsahovat obsah vytvořený komunitou, za který společnost Trading 212 nenese odpovědnost. Vždy prováděj vlastní průzkum. Trading 212 poskytuje pouze exekuční služby a nenabízí investiční poradenství ani správu portfolia.
Tvorba bohatství je zvyk. Automatizuj ho pomocí Pie.
Investuj do předpřipravených pies, nebo si vytvoř své vlastní výběrem z tisíců akcií a ETF
Zjistit více
Zjistit více
Zhlédnout video
Vlastni i ty nejdražší akcie jako Google, Amazon a Apple
Zhlédnout video
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
London Stock Exchange
Euronext Lisabon
Euronext Paris
NYSE, NASDAQ
Xetra, Gettex
Euronext Amsterdam
Bolsa de Madrid
Wiener Börse
London Stock Exchange
Euronext Lisabon
Zobrazit všechny obchodní nástroje
Podpora 24/7
Průměrná doba odezvy 29 sekund
Začni budovat své bohatství teď
Přidej se k více než 5 milionům uživatelů
Získat aplikaci
Otevřít účet
Získej mobilní aplikaci
Všechny prezentované statistiky jsou globální. Počet klientů představuje financované účty.
Skvělé
Hodnoceno 4,6 / 5 založeno na 93 567 hodnoceních
Trustpilot
Hodnoceno 4,6 / 5 založeno na 93 567 hodnoceních
Trustpilot
Pozvaní
Great
Immediate updates, easy to use and manage.
Pozvaní
Very easy to use
Very easy to use. Intuitive app and makes it straight forward to sit back and let your investment's do its work
Pozvaní
Ease of use
Easy to set up an account
Easy to transfer funds
Great interest rate
Great all round experience
Pozvaní
Easy to set up my account
Easy to set up my account easy to access balance and a very good rate in interest.
Pozvaní
easy to use platform
easy to use platform, love the ability to transfer cash isa funds into stocks and shares isa
Pozvaní
Simple and Informative platform
I wanted a platform which was offering great rates for my ISA, but discovered not only did this platform do that. It also gave me an insight into trading and world markets. It's quite simply brilliant.
Pozvaní
Great app that provides all my account…
Great app that provides all my account info at my fingertips
Pozvaní
Easy to use.
Easy to use.
Can view everything simply.
Just what I need.
Pozvaní
Good interest rate and can take the…
Good interest rate and can take the money out whenever I want.
Pozvaní
So easy
So easy! Makes investing a pleasure
Pozvaní
I’m novice and useless with technology…
I’m novice and useless with technology but I found this an easy site to navigate and to deal with.
Pozvaní
Nice app
Great app, very intuitive and simple to use. Gold standard.
Pozvaní
Very easy to use
Very easy to use. Very clear. And a joy to watch my savings rise
Pozvaní
Easy to use
Functional and easy to use and track my cash & stocks & shares isas
Pozvaní
Easy access to my account and how Easy…
Easy access to my account and how Easy it is to navigate the212 application.
Pozvaní
Simple and easy to use app
Simple and easy to use app. Ease of setting up recurring payments. Great for a beginner that has no prior knowledge or experience of investing.
Pozvaní
Easy and simple app
Easy and simple app, tells you daily your interest which I like and I get emails. The updating is really good.
Pozvaní
Very easy and highly recommend
Very easy and highly recommend. Straight forward to use and cost instructions on the fees and charges.
Pozvaní
Great way for your money to build
Just very pleased with the level of savings rate and steady build up.
Pozvaní
Cool app
User friendly mobile app that makes investing easy and funny. Fast navigation throughout the app. In a few clicks can see basically every information one might require.
Zobrazí se některé z pozitivních recenzí našich klientů
Naše ocenění
Často kladené otázky
Jaká je cena akcie GSK (GSK)?
Aktuální cena GSK (GSK) je 1 900,3 GBX.
Jaké je 52týdenní maximum GSK?
52týdenní maximum pro GSK je 2 281,7 GBX.
Jaké je 52týdenní minimum GSK?
52týdenní minimum pro GSK je 1 318,7 GBX.
Jaký je týdenní výkon GSK?
Za poslední týden se cena GSK změnila o -0,92 %.
Jaký je měsíční výkon GSK?
Za poslední měsíc se cena GSK změnila o -0,04 %.
Jaký je 3měsíční výkon GSK?
Za poslední tři měsíce se cena GSK změnila o -10,45 %.
Jaký je 6měsíční výkon GSK?
Za posledních šest měsíců se cena GSK změnila o 3,67 %.